Author:
Luma Henry Namme,Mboringong Fanny,Doualla Marie-Solange,Nji Miriam,Donfack Olivier-Tresor,Kamdem Felicite,Ngouadjeu Eveline,Lepka Fernando Kemta,Mapoure Yakouba Njankou,Mbatchou Hugo Bertrand
Abstract
Background:
With easy accessibility to combination Antiretroviral Therapy (cART), mortality amongst hospitalized HIV/AIDS patients needs to be described.
Objective:
We aimed at determining the trends, causes and factors associated with in-hospital mortality amongst HIV/AIDS patients in the Douala General Hospital.
Methods:
We retrospectively reviewed hospitalisation records of HIV/AIDS patients hospitalized in the medical wards of the DGH from 2007 to 2015. Four cause-of-death categories were defined: 1. Communicable conditions and AIDS-defining malignancies, 2. Chronic non-communicable conditions and non-AIDS defining malignancies’, 3. Other non-communicable conditions and 4. Unknown conditions. Logistic regression was used to determine factors associated mortality.
Results:
We analyzed 891 eligible files. The mean age was 43 (standard deviation (SD): 10) years and median length of hospital stay was 9 (interquatile range (IQR)4 - 15) days. The overall all-cause mortality was 23.5% (95% CI: 20.8% - 26.4%). The category - communicable conditions and AIDS defining malignancies represented 79.9%, of deaths and this remained constant for each year during the study period. Tuberculosis was the most common specific cause of death (23.9%). Patients who had two (OR=2.35, 95%CI: 1.35 - 4.06) and more than two (OR=4.23, 95%CI: 1.62 – 11.12) opportunistic infections, a haemoglobin level less than 10g/l (OR=2.38, 95%CI: 1.58 - 3.59) had increased odds of dying.
Conclusion:
In-hospital mortality is high amongst HIV/AIDS patients at the Douala general hospital. The category - communicable conditions and AIDS defining malignancies - is still the main underlying cause of death. We hope that our findings will help to develop interventions aimed at reducing in-hospital mortality.
Publisher
Bentham Science Publishers Ltd.
Subject
Virology,Infectious Diseases,Public Health, Environmental and Occupational Health
Reference48 articles.
1. UNAIDS
2017.
Available from: http:/ /www.aidsdatahub.org/ sites/default/ files/ publication/ UNAIDS_Global_ AIDS_Update_ 2017_Data _book_2017 _en.pdf.
2. WHO.
Summary of the global HIV epidemic
2016.
Available from: http://www.who.int/hiv/data/epi_core_2016.png
3. WHO.
World Health Organization WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children 2007
2007.
4. Stebbing J, Bower M, Mandalia S, Nelson M, Gazzard B.
Highly Active Anti-Retroviral Therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality.
Clin Exp Immunol
2006;
145
(2)
: 271-6.
5. Brechtl JR, Breitbart W, Galietta M, Krivo S, Rosenfeld B.
The use of Highly Active Anti-Retroviral Therapy (HAART) in patients with advanced HIV infection: Impact on medical, palliative care, and quality of life outcomes.
J Pain Symptom Manage
2001;
21
(1)
: 41-51.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献